Merck KGaA (FRA:MRK) PT Set at €100.00 by Commerzbank

Commerzbank set a €100.00 ($116.28) price target on Merck KGaA (FRA:MRK) in a research note issued to investors on Wednesday, September 12th. The brokerage currently has a buy rating on the healthcare company’s stock.

A number of other research analysts have also issued reports on MRK. Sanford C. Bernstein set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Tuesday, July 3rd. Societe Generale set a €88.00 ($102.33) price target on shares of Merck KGaA and gave the company a neutral rating in a research note on Wednesday, July 4th. Berenberg Bank set a €104.00 ($120.93) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Wednesday, July 4th. UBS Group set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Tuesday, June 26th. Finally, Warburg Research set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Tuesday, July 3rd. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of Hold and an average target price of €98.71 ($114.78).

Merck KGaA stock traded up €0.64 ($0.74) during mid-day trading on Wednesday, reaching €89.44 ($104.00). 621,983 shares of the company traded hands. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: Marijuana Stocks Future Looks Bright

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply